Aperio Group LLC grew its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 8.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 63,557 shares of the biotechnology company’s stock after acquiring an additional 5,212 shares during the quarter. Aperio Group LLC’s holdings in Exelixis were worth $1,540,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also recently bought and sold shares of EXEL. First Quadrant L P CA purchased a new position in Exelixis during the 2nd quarter worth $144,000. Fisher Asset Management LLC purchased a new position in Exelixis during the 3rd quarter worth $213,000. Wetherby Asset Management Inc. purchased a new position in Exelixis during the 2nd quarter worth $218,000. Caxton Associates LP purchased a new position in Exelixis during the 2nd quarter worth $227,000. Finally, Capstone Asset Management Co. purchased a new position in Exelixis during the 2nd quarter worth $242,000. 78.06% of the stock is currently owned by hedge funds and other institutional investors.
In related news, insider Gisela Schwab sold 100,000 shares of the business’s stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $23.79, for a total value of $2,379,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Stelios Papadopoulos sold 10,000 shares of the business’s stock in a transaction dated Friday, September 22nd. The shares were sold at an average price of $25.40, for a total value of $254,000.00. The disclosure for this sale can be found here. Insiders sold a total of 970,152 shares of company stock worth $25,923,457 over the last 90 days. 5.10% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Aperio Group LLC Boosts Position in Exelixis, Inc. (EXEL)” was published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.truebluetribune.com/2017/11/16/aperio-group-llc-boosts-position-in-exelixis-inc-exel.html.
A number of equities analysts have issued reports on the stock. TheStreet raised shares of Exelixis from a “c+” rating to a “b-” rating in a report on Wednesday, October 18th. Zacks Investment Research raised shares of Exelixis from a “hold” rating to a “buy” rating and set a $32.00 price objective on the stock in a report on Wednesday, October 18th. Needham & Company LLC lifted their price objective on shares of Exelixis from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Tuesday, October 17th. Royal Bank Of Canada lifted their price objective on shares of Exelixis from $33.00 to $39.00 and gave the stock an “outperform” rating in a report on Tuesday, October 17th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $26.00 price objective on shares of Exelixis in a report on Tuesday, October 17th. Six analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $31.38.
Shares of Exelixis, Inc. (EXEL) opened at $24.75 on Thursday. The company has a market capitalization of $7,320.00, a price-to-earnings ratio of 49.24, a PEG ratio of 1.13 and a beta of 1.89. Exelixis, Inc. has a 52 week low of $14.22 and a 52 week high of $32.50.
Exelixis (NASDAQ:EXEL) last released its earnings results on Wednesday, November 1st. The biotechnology company reported $0.26 EPS for the quarter, topping the Zacks’ consensus estimate of $0.08 by $0.18. The company had revenue of $152.50 million for the quarter, compared to analysts’ expectations of $104.91 million. Exelixis had a return on equity of 105.47% and a net margin of 36.80%. The business’s revenue for the quarter was up 145.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.04) EPS. equities analysts expect that Exelixis, Inc. will post 0.49 EPS for the current year.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.